Welcome, Guest. Please login or register.
July 19, 2019, 12:33:32 am

Login with username, password and session length

  • Total Members: 34537
  • Latest: Anxi
  • Total Posts: 746098
  • Total Topics: 62413
  • Online Today: 272
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 am)
Users Online
Users: 1
Guests: 266
Total: 267


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: The long tail of injectable PrEP is especially long for women  (Read 494 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 12,491
  • Twitter @JimAllenDublin
    • HIV Lessons
The long tail of injectable PrEP is especially long for women
« on: October 27, 2018, 04:51:40 am »
Long-acting injectable PrEP has shown to be effective in studies but there are some concerns about the potential development of drug resistance as there is a lengthy period post stopping injectable PrEP that they have low levels of the drugs during which, if they caught HIV, they could develop drug resistance.

Full write-up here: http://www.aidsmap.com/page/3357646/

Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around 18 months after their last injection, Raphael Landovitz of the University of California told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid yesterday. While providing evidence of the durability and potency of injectable cabotegravir, the findings raise concerns about the potential development of drug resistance.

If people stop receiving PrEP injections, they will be vulnerable to HIV unless they start or continue another method of HIV prevention, such as oral PrEP. In addition, the ‘long tail’ in some people means that there is a lengthy period during which, if they caught HIV, they could develop drug resistance. Drug resistance only arises in situations like this when there is some drug in the body but not enough to fully suppress an infection.

The problem was first identified two years ago in the ECLAIR study, whose participants were all American men. In order to better understand the issue, follow-up in another study, HPTN 077, was extended from 48 to 76 weeks (approximately 18 months) after participants’ last injection. This phase II study was designed to examine the safety, tolerability and pharmacodynamics of injectable cabotegravir, but not its efficacy.

This study recruited 199 women and men in the United States, South Africa, Malawi and Brazil who did not have HIV and were at low risk of acquiring it.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.